PI3K/Akt inhibitor, LY294002, synergizes with VCR to promote the growth inhibition of gastric cancer cells and inhibit tumor invasion and migration, which in turn induces apoptosis, and increases intracellular drug accumulation, as well as improves cancer cell sensitivity to VCR. This evidence concerns the gene AKT1 and neoplasm.